Neurotech launches Mente Autism

Company News

Neurotech International (ASX:NTI) has conducted the official marketing launch of Mente Autism.

Mente Autism is a clinical-quality EEG device that uses neuro feedback technology to help children with autism spectrum disorder (ASD).

Designed for home use, Mente Autism helps relax the minds of children on the spectrum which in turns helps them to focus better and engage positively with their environment.

The marketing launch follows receipt of CE Marking for Mente Autism in Europe as a Class IIa medical device

Local registration for Mente Autism has now commenced in Italy, along with training of the local distributor’s sales teams and medical experts, with additional marketing initiatives occurring in parallel. 

Neurotech management said it expects these efforts to culminate in the first shipment of Mente Autism devices to the Italian distributor within the current quarter.

The company said rollout of the Mente Autism device will occur on a country-by-country basis subject to local registration requirements, with initial efforts focussed on key European markets.

As part of the marketing launch for Mente Autism, Neurotech management will be present at this week's Medica International Trade Fair in Düsseldorf, Germany, which is considered one of the world’s leading trade fairs within the medical industry. 

“The company expects to receive local registration of Mente Autism within Italy in the coming weeks, that being the final step before we can deliver the first devices,” said CEO Wolfgang Storf.

“We have received widespread interest in the product and look forward to witnessing initial sales of the third iteration of the Mente system, as well as realising first revenues from the device.”

“Mente Autism possesses various upgraded features to improve the performance, convenience and comfort of the device,” said Neurotech’s Founder and Chief Scientific Officer, Dr Adrian Attard Trevisan.

“The biggest change sees it now come as a self-contained headband, not requiring connectivity to a smartphone or tablet during the therapy session and therefore allowing the child to move around more freely in that time. The buckle has been centred to provide improved pressure distribution and improves Mente Autism’s capability as a full EEG monitoring device, using five high performance and replaceable sensors. “Importantly we have now established a clinical grade retail platform with Mente Autism, which will allow us to more easily adapt the device for the treatment of other neurological disorders such as epilepsy, anxiety, depression and tinnitus.”